Brand Dolo being expanded in OTC space via Micro Wellness
As lifestyle diseases continue to rise, Micro Labs, the maker of Dolo, is expanding its focus on its newly structured wellness segment. The company is capitalising on the popularity of the Dolo brand by launching an over-the-counter segment under the same name such as Dolo pain relief spray, Dolosils Cough Lozenges or Dolo Fevometer. “From lozenges, gel sprays, thermometers, antacids, and nicotine gums, we are significantly expanding our wellness product offerings. This strategic move aligns with the growing demand for lifestyle solutions, complementing our existing focus on chronic disease therapies," Diya Surana, head, strategy, digital transformation and OTC wellness, Micro Labs told News18 in her first exclusive interaction.
Micro Labs has acquired Swiss Pharma Nigeria Limited (Swipha)
As part of efforts to expand its footprints across African Continent, Micro Labs Limited (Micro Labs), India has acquired Swiss Pharma Nigeria Limited (Swipha), a leading pharmaceutical company in Nigeria.
Introducing Trisopt: The World's First Triple Drug Combo for Glaucoma
Micro Labs Ltd introduces Trisopt: World’s first triple drug fixed-dose combination for Glaucoma Management.Trisopt is an indigenous development from Micro Labs, manufactured in their state-of-the-art facility located in Sikkim.
Micro Labs Ltd, disrupting the Indian pharmaceutical industry since 1973
Today, Dolo-650 is the 6th largest brand (as per AWACS) in the Indian Pharmaceutical Market became the number one prescribed brand of paracetamol solid oral doses in India.
The Brand Story Media recognized Dolo-650 as India’s leading brand
Dolo-650 gets recognized as India’s Leading Brand at the Indian Brand and Leadership Conclave 2022 organized by The Brand Story.
How Micro Labs struck Gold with Dolo-650
The company has sold 350 crore tablets since the Covid-19 outbreak in 2020, and earned revenues of Rs 400 crore in a year
How Dolo 650 became the Go to Drug during the pandemic
Easy availability and being the doctors’ preferred prescription during the second wave.